Back

Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation: a propensity-weighted cohort study

26 August 2018 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Atrial fibrillation - Stroke prevention - General Oral Anticoagulation ESC Premium Access ESC Congress 2018

About the speaker

Photo
Associate Professor Erik Lerkevang Grove

Aarhus University Hospital, Aarhus (Denmark)

8 More presentations in this session

Presentation thumbnail
Ms K. Pieper (London, GB)
Abstract Slides
Presentation thumbnail
Professor G. Lip (Liverpool, GB)
Abstract Slides
Presentation thumbnail
Professor U. Zeymer (Ludwigshafen, DE)
Abstract
Presentation thumbnail
Doctor X. Li (Princeton, US)
Abstract Slides
Presentation thumbnail
Professor A. Bisson (Tours, FR)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 3 - Atrial fibrillation - Stroke prevention - General

The Event

Event poster

ESC Congress 2018

26 August 2018 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Adherence and treatment satisfaction among atrial fibrillation patients treated with VKAs versus NOACs: real-world data from a single-center cohort
12 April 2026
thumbnail
Congress Presentation
Direct oral anticoagulants versus left atrial appendage closure in elderly patients (>80) with atrial fibrillation: results from a propensity matched analysis in real-life patients
28 August 2020
thumbnail
Congress Presentation
Association between personalized evidence-based anticoagulation therapy and outcomes at 1-year follow-up in patients with atrial fibrillation: an analysis from the Atrial Fibrillation Registry
29 June 2021
thumbnail
Congress Presentation
Direct oral anticoagulants compared to warfarin in morbidly obese patients on anticoagulation: a systematic review and meta-analysis
26 April 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources